Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy

Related Clinical Trial
Total Marrow Irradiation for Refractory Acute Leukemia Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Leukemia After Undergoing Donor Stem Cell Transplant MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Symptom-Adapted Physical Activity Intervention in Minimizing Physical Function Decline in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy A Phase II Study Of The Farnesyltransferase Inhibitor ZANESTRA (R115777, NSC #702818, IND #58,359) In Complete Remission Following Induction And/Or Consolidation Chemotherapy In Adults With Poor-Risk Acute Myelogenous Leukemia (AML) And High-Risk Myelodysplasia (MDS) Radiolabeled BC8 Antibody, Busulfan, Cyclophosphamide Followed by Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia in First Remission 3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic Malignancies Busulfan and Etoposide Followed by Peripheral Blood Stem Cell Transplant and Low-Dose Aldesleukin in Treating Patients With Acute Myeloid Leukemia Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission Decitabine in Treating Patients With Previously Untreated Acute Myeloid Leukemia GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous Leukemia PXD101 in Treating Patients With Acute Myeloid Leukemia Decitabine and Valproic Acid in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies Lenalidomide and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Bendamustine and Idarubicin in Treating Older Patients With Previously Untreated AML or MDS Clofarabine and Cytarabine in Treating Patients With Acute Myeloid Leukemia With Minimal Residual Disease Total Marrow and Lymphoid Irradiation and Chemotherapy Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Lymphocytic or Myelogenous Leukemia Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Tosedostat in Combination With Cytarabine or Decitabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Decitabine, Donor Natural Killer Cells, and Aldesleukin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Decitabine and Bortezomib in Treating Patients With Acute Myeloid Leukemia Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chronic Lymphocytic Leukemia Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Acute Myeloid Leukemia GTI-2040 and High-Dose Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia Connect® MDS/AML Disease Registry Combined PD1 Inhibitor and Decitabine in Elderly Patients With Relapse and Refractory Acute Myeloid Leukemia Vorinostat in Treating Patients With Acute Myeloid Leukemia Clofarabine, Cytarabine, and G-CSF in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid Leukemia Decitabine in Treating Children With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia Economic Analysis of Blood Product Transfusions According to the Treatment of Acute Myeloid Leukaemia in the Elderly Comparison of Diagnostic Yield Among M-FISH, FISH Probe Panel and Conventional Cytogenetic Analysis in AML Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid Leukemia Bortezomib in Treating Young Patients With Refractory or Recurrent Leukemia Red Cell Transfusion Goals in Patients With Acute Leukemias A PALG Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in AML Patients ≤ 60 Years Old An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia Fludarabine and Cytarabine as Continuous Infusion Plus G-CSF Priming for Elderly Patients With Resistant AML Phase I/II Trial of ATRA and TCP in Patients With Relapsed or Refractory AML and no Intensive Treatment is Possible Prognostic Values of Next Generation Sequencing (NGS) in Acute Myeloid Leukemia Patients With Allo-HSCT PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia Pilot Clinical Trial of Pazopanib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When no Intensive Treatment is Possible A Safety Study of SGN-CD33A in AML Patients FLAG+Ida With G-CSF Priming for Patients Younger Than 60 Years With Resistant AML Study on Number and Outcome of Pregnancy in Acute Promielocitic Leukaemia (APL) Patients Treated With Chemotherapy Biomarkers in Bone Marrow Samples From Patients With Acute Promyelocytic Leukemia Treatment Study for Children and Adolescents With Acute Promyelocitic Leukemia A Study for Improving the Outcome of Childhood Acute Promyeloid Leukemia ASCT for Relapsed APL After Molecular Remission Diagnostic Study of Patients With Acute Lymphoblastic Leukemia or Acute Promyelocytic Leukemia National Acute Promyelocytic Leukemia (APL) Observational Study NAPOLEON-Registry of the German AML Intergroup All-trans Retinoic Acid, and Arsenic +/- Idarubicin Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APL Randomized,International Multi-center Clinical Trial of RIF Plus RA for Non-high-risk APL Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia AIDA 2000 Guidelines Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia The Acute Promyelocytic Leukaemia Asian Consortium (APL-AC) Project Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL French Registry of First-line Treatment of Acute Promyelocytic Leukemia New Retinoid Agent Combined With Arsenic Trioxide for Untreated Acute Promyelocytic Leukemia Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO) Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005) Long-Term Quality of Life in Patients With Acute Promyelocytic Leukemia Tamibarotene and Arsenic Trioxide for Relapsed Acute Promyelocytic Leukemia Long-term QoL in Acute Promyelocytic Leukemia Treated With ATO or Standard Chemotherapy Treatment of Non-high-risk Acute Promyelocytic Leukemia (APL) With Realgar-Indigo Naturalis Formula (RIF) Treatment of Acute Promyelocytic Leukemia With All-Trans Retinoic Acid (ATRA) and Idarubicin (AIDA) Single Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia Treatment Protocol for Relapsed Acute Promyelocytic Leukemia (APL) With Arsenic Study of NRX 195183 Therapy for Patients With Relapsed or Refractory Acute Promyelocytic Leukemia Oral Arsenic Trioxide for Newly Diagnosed Acute Promyelocytic Leukaemia Role of Microparticles in the Coagulopathy of Acute Promyelocytic Leukemia Proteasome Inhibition in Acute Promyelocytic Leukemia

Brief Title

Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy

Official Title

A Phase II Study of Azacitidine and Sirolimus for the Treatment of High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Refractory to or Not Eligible for Intensive Chemotherapy

Brief Summary

      This phase II trial studies how well sirolimus and azacitidine works in treating patients
      with high-risk myelodysplastic syndrome or recurrent acute myeloid leukemia. Sirolimus may
      stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs
      used in chemotherapy, such as azacitidine, work in different ways to stop the growth of
      cancer cells, either by killing the cells or by stopping them from dividing. Sirolimus and
      azacitidine may kill more cancer cells.
    

Detailed Description

      PRIMARY OBJECTIVE:

      I. To characterize the rate of response to azacitidine and sirolimus in adults with high-risk
      myelodysplastic syndrome (MDS), or relapsed or refractory acute myeloid leukemia (AML) or
      those unable or unwilling to tolerate high dose chemotherapy.

      SECONDARY OBJECTIVES:

      I. To determine the pharmacodynamic effect of sirolimus on inhibition of mammalian target of
      rapamycin (mTOR) signaling in adults with high-risk MDS, or relapsed or refractory AML or
      those unable or unwilling to tolerate high dose chemotherapy.

      II. To determine the safety and tolerability of sirolimus and azacitidine in adults with
      high-risk MDS, or relapsed or refractory AML or those unable or unwilling to tolerate high
      dose chemotherapy.

      III. To determine the progression free survival and overall survival in adults with high-risk
      MDS, or relapsed or refractory AML or those unable or unwilling to tolerate high dose
      chemotherapy.

      IV. To determine if the quality of life of patients is improved with the combination of
      azacitidine and sirolimus when compared to historical controls of azacitidine alone.

      OUTLINE:

      Patients receive sirolimus orally (PO) on days 1-10 or 1-12 and azacitidine intravenously
      (IV) on days 4-8, 11, and 12 or days 4-10. Treatment repeats every 28 days in the absence of
      disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up every 3 months.
    

Study Phase

Phase 2

Study Type

Interventional


Primary Outcome

Rate of response

Secondary Outcome

 Toxicity referring to toxic events during the full course of treatment that are attributed as possibly, probably or definitely due to treatment, graded according to the National Institutes of Health (NIH) Common Toxicity Criteria (CTC) v. 4.0

Condition

Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities

Intervention

Sirolimus

Study Arms / Comparison Groups

 High risk Myleodysplastic Syndrome (MDS)
Description:  Patients receive sirolimus PO on days 1-10 or 1-12 and azacitidine IV on days 4-8, 11, and 12 or days 4-10. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

57

Start Date

July 8, 2013

Completion Date

July 1, 2021

Primary Completion Date

July 1, 2020

Eligibility Criteria

        Inclusion Criteria:

          1. Patients must have a diagnosis of one of the following:

               -  MDS (Arm A): High-risk MDS defined as: >5% blasts in bone marrow and/or the
                  following cytogenetic categories: presence of inv(3)/t(3q)/del(3q), -7/del(7q),
                  complex cytogenetics (3 or more abnormalities)

               -  AML (Arm B): Relapsed/refractory/unable to tolerate conventional chemotherapy

               -  MDS or AML as above BUT with prior therapy with Azacitibine (Arm C): Patients who
                  meet criteria for either Arm A or Arm B but have been treated or are currently
                  treated with Azacitibine *Note: As of July 2018, only high risk MDS patients will
                  be eligible as Arm B is closed. As of October 2017, those patients with MDS who
                  have received prior treatment will now be enrolled in Arm A as Arm C is closed.

          2. Patients must be ≥ 18 years old

          3. Patients must have an ECOG performance status of <= 2 (see Attachment 1).

          4. Patients must have a life expectancy of at least 4 weeks.

          5. Patients must be able to consume oral medication.

          6. Patients must have completed any radiotherapy four weeks prior to study entry, 0-2
             weeks for local palliative XRT (small port).

          7. Patients must have recovered from the toxic effects of any prior chemotherapy to <
             Grade 2 (except for alopecia).

          8. Required initial laboratory values: Creatinine≤ 2.0mg/dL; total or direct bilirubin ≤
             1.5mg/dL (if not due to the leukemia itself or known Gilbert's Syndrome);(as
             documented by treating physician) SGPT(ALT) ≤ 3xULN; glucose <200 mg/dL, negative
             pregnancy test for women of child-bearing potential.

          9. Patients must be able to sign consent and be willing and able to comply with scheduled
             visits, treatment plan and laboratory testing.

         10. Patients may have had a prior stem cell transplant (autologous or allogeneic), however
             they may not have active GvHD, nor be on any immunosuppression

        Exclusion Criteria:

          1. Patients must not be receiving any chemotherapy agents (except Hydroxyurea)

               -  Intrathecal ARA-C and intrathecal methotrexate are permissible (as they are not
                  systemic and only isolated to the central nervous system).

               -  Patients can not have received more than 3 prior lines of therapy for their
                  hematologic malignancy. Patient may have previously had azacitidine or decitabine
                  will be eligible to enroll on Arm A (MDS)

          2. Patients must not be receiving growth factors.

          3. Patients with a current second malignancy requiring systemic therapy, other than
             non-melanoma skin cancers, are not eligible. If a patient has had a prior second
             malignancy that is not currently requiring active treatment, the patient will be
             considered eligible.

          4. Patients with uncontrolled high blood pressure, unstable angina, symptomatic
             congestive heart failure, myocardial infarction within the past 6 months or serious
             uncontrolled cardiac arrhythmia are not eligible.

          5. Patients may not take any of the following medications while on study, but will be
             considered eligible if medication is discontinued 72 hrs prior to first dose of
             Sirolimus:

               -  Carbamazepine (e.g. Tegretol)

               -  Rifabutin (e.g. Mycobutin)

               -  Rifampin (e.g. Rifadin)

               -  Rifapentine (e.g. Priftin)

               -  St. John's Wort- may decrease effects of sirolimus by decreasing the amount of
                  sirolimus in the body

               -  Clarithromycin (e.g. Biaxin)

               -  Cyclosporin e.g. (Neoral or Sandimmune)

               -  Diltiazem (e.g. Cardizem)

               -  Erythromycin (e.g. Akne-Mycin, Ery-Tab)

               -  Itraconazole (e.g. Sporanox)

               -  Fluconazole (e.g. Diflucan)

               -  Ketoconazole (e.g. Nizoral)

               -  Telithromycin (e.g. Ketek)

               -  Verapamil (e.g. Calan SR, Isoptin, Verelan)

               -  Voriconazole (e.g. VFEND) - May increase the effects of sirolimus by increasing
                  the amount of this medicine in the body. Can take 72 hours after last dose of
                  Sirolimus

               -  Tacrolimus (e.g. Prograf) - May cause liver transplant rejection or serious side
                  effects in patients on sirolimus.

          6. Patients with known HIV positivity or AIDS-related illness are not eligible.

          7. Patients with other severe concurrent disease which in the judgment of the
             investigator would make the patient inappropriate for entry into this study are
             ineligible.

          8. Patients must not have received any investigational agents within 21days of study
             entry.

          9. Patients must not be pregnant or breastfeeding. Pregnancy tests must be obtained for
             all females of child-bearing potential. Pregnant or lactating patients are ineligible
             for this study due to the unknown human fetal or teratogenic toxicities of rapamycin.
             Males or females of reproductive age may not participate unless they have agreed to
             use an effective contraceptive method.

         10. Patients who have uncontrolled infection are not eligible. Patients must have any
             active infections under control. Fungal disease must be stable for at least 2 weeks
             before study entry. Patients with bacteremia must have documented negative blood
             cultures prior to study entry.
      

Gender

All

Ages

18 Years - N/A

Accepts Healthy Volunteers

No

Contacts

Neil Palmisiano, MD, , 

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT01869114

Organization ID

12D.587

Secondary IDs

2012-50

Responsible Party

Sponsor

Study Sponsor

Sidney Kimmel Cancer Center at Thomas Jefferson University


Study Sponsor

Neil Palmisiano, MD, Principal Investigator, Sidney Kimmel Cancer Center at Thomas Jefferson University


Verification Date

February 2020